Packaging & Labelling
Pharmapack Europe 2018 to Spotlight New Innovations and the Young Innovators who are Shaping the Industry
Pharmapack Europe 2018 , Europe’s dedicated pharmaceutical packaging and drug delivery conference and exhibition, organised by UBM EMEA, is taking place on 7–8 February...
Drug Research
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China
Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate...
News
BioGeneration Ventures Fund III Secures EUR 66m, exceeding EUR 50m target
BioGeneration Ventures (BGV), the early stage life sciences venture capital firm with funds focussed on European biotechnology companies, announces an investment by the European...
Clinical Trials
Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
Boston Biomedical Inc, announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced...
News
Technology selection identified as biggest hurdle in serialization race for compliance
New industry research explores the greatest barriers to serialization success as companies across the pharmaceutical supply chain prepare for new regulations in the US...
Press Releases
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan
Eisai Co., Ltd. announced that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic...
Clinical Trials
OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers
OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate for cancer immunotherapy. Submission of the Company's second Investigational New...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read